Kemira appoints Tuula Paajanen as Director, Corporate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
65
Kemira appoints Tuula Paajanen as Director, Corporate Responsibility

Kemira Oyj Press Release April 21, 2017 at 1.00 apm (CET+1)

Kemira appoints Tuula Paajanen as Director, Corporate Responsibility

Tuula Paajanen (Master of Science, Chem.Eng) has been appointed Director, Corporate Responsibility at Kemira starting in May, 2017. She has previously been working in Kemira's corporate responsibility team and held various leadership positions during her 15 years successful career in the company. "Tuula has played a significant role in building and continuously improving our sustainability performance, monitoring and reporting. I am confident that going forward, Tuula will continue to bring new valuable insights into this work and improve Kemira's corporate responsibility performance further" says Tero Huovinen , SVP, Communications. "Sustainability is an integral part of Kemira's strategy and business model for growth and value creation. Our commitment for sustainable products and solutions stands for improved resource and process efficiency for our customers and safe use of our products throughout their lifecycle. We take responsibility on the impacts of our business activities in all areas of our operations including manufacturing and supply chain. Our stakeholders expect high sustainability performance from us which drives our efforts to continuously improve our business processes to meet these growing expectations," says Jari Rosendal , Kemira's President and CEO. For more information, please contact Kemira Oyj Tero Huovinen, SVP, Communications Tel. +358 10 862 1980

 

Kemira is a global chemicals company serving customers in water-intensive industries. We provide expertise, application know-how and chemicals that improve our customers' product quality, process and resource efficiency. Our focus is on pulp & paper, oil & gas, mining and water treatment. In 2016, Kemira had annual revenue of around EUR 2.4 billion and 4,800 employees. Kemira shares are listed on the Nasdaq Helsinki Ltd. www.kemira.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading